%0 Journal Article %T Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study %+ Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes] %+ Foie, métabolismes et cancer %+ Centre d'Investigation Clinique [Rennes] (CIC) %+ Service d'Hépato-gastro-entérologie [CHRU Nancy] %+ Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE) %+ Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E) %A Mallet, Anne-Laure %A Bouguen, Guillaume %A Conroy, Guillaume %A Roblin, Xavier %A Delobel, Jean-Bernard %A Bretagne, Jean-François %A Siproudhis, Laurent %A Peyrin-Biroulet, Laurent %< avec comité de lecture %@ 1590-8658 %J Digestive and Liver Disease %I Elsevier %V 49 %N 3 %P 280-285 %8 2017-03 %D 2017 %R 10.1016/j.dld.2016.12.001 %M 28089625 %K Proctitis %K Ulcerative colitis %K Azathioprine %Z Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology %Z Life Sciences [q-bio]/Pharmaceutical sciences/MedicationJournal articles %X BACKGROUND: Efficacy of azathioprine (AZA) in refractory ulcerative proctitis (UP) is unknown.METHODS: All patients treated with AZA for refractory UP in three referral centers between 2002 and 2012 were included. "Treatment success" in the long-term was defined as the absence of colectomy during follow-up, no need for anti-TNF during follow-up, no ongoing systemic steroids use, no adverse event leading to AZA withdrawal, and clinically quiescent disease at last follow-up.RESULTS: Of the 1279 adult patients with ulcerative colitis, 25 patients were treated with AZA for refractory UP (median disease duration 4.9 years). Of these, 4 had no short-term clinical assessment. Of the remaining 21, 4 were primary non responders to AZA, 7 discontinued AZA for adverse events and 10 showed clinical improvement. At the long-term assessment at last follow up after a median of 46 months, 5 patients had treatment success and were still on AZA treatment, the remaining 20 were treatment failures. Of these, 5 discontinued AZA for adverse events and 15 were treated with infliximab (clinical response in 11 patients, primary non-response in one patient, and 3 underwent colectomy).CONCLUSION: AZA may be efficacious in maintaining clinical response in one-fifth of patients with refractory UP in a real-life setting. %G English %2 https://univ-rennes.hal.science/hal-01483854/document %2 https://univ-rennes.hal.science/hal-01483854/file/Mallet%20et%20al.%20-%20AZATHIOPRINE%20FOR%20REFRACTORY%20ULCERATIVE%20PROCTITIS%20.pdf %L hal-01483854 %U https://univ-rennes.hal.science/hal-01483854 %~ INSERM %~ UNIV-RENNES1 %~ IFR140 %~ HL %~ CIC %~ CIC203 %~ U991 %~ U991-E2 %~ STATS-UR1 %~ UNIV-LORRAINE %~ NUMECAN %~ NUMECAN-EXPRES %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ TEST-UNIV-RENNES %~ TEST-UR-CSS %~ UNIV-RENNES %~ NGERE-UL %~ BMS-UL %~ UR1-BIO-SA %~ TEST3-HALCNRS